CLINICAL STUDY
COMPARATIVE STUDY
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.

BACKGROUND: Interstitial lung disease (ILD) is one of the most common and devastated complication of polymyositis/dermatomyositis (PM/DM). Several studies have focused on serum biomarkers for ILD in PM/DM patients; however, there have been no prospective studies.

AIM: To explore and compare the predictive value of four serum markers for the development of ILD in patients with PM/DM.

METHODS: One hundred adult PM/DM patients were included in this prospective clinical study at baseline. Forty-four PM/DM patients without ILD were followed up for 1 year. Fifty-six PM/DM patients with ILD were treated and followed up for 2 months. Serum samples were analysed for the levels of Krebs von den Lungen-6 (KL-6), monocyte chemotactic protein-1 (MCP-1), surfactant protein-A and D (SP-A, SP-D).

RESULTS: Serum KL-6 (1542.8 ± 760.8 U/mL) (P < 0.001), MCP-1 (1870 ± 1590 pg/mL) (P = 0.014), SP-A (56 ± 28 ng/mL) (P < 0.001) and SP-D (230 ± 196 ng/mL) (P < 0.001) were significantly elevated in PM/DM patients with ILD compared with those in the patients without ILD (KL-6 429 ± 105.8 U/mL; MCP-1 1349 ± 1303 pg/mL; SP-A 34 ± 26 ng/mL; SP-D 96 ± 63 ng/mL). In PM/DM patients without ILD who were followed up for 1 year, KL-6 presented the highest predictive value among single markers. In patients who were treated and followed up, KL-6 concentrations increased with the progression of ILD and decreased along with the improvement of ILD.

CONCLUSION: Considering the ability of KL-6 for predicting the onset of ILD and monitoring the treatment response of ILD in PM/DM patients, it may be of great significance for clinical practice, and the prognosis of patients may be substantially improved if serum KL-6 was regularly monitored.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app